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ABSTRACT 
 
OBJECTIVE: Mitotane, a drug used to treat adrenocortical cancer (ACC), inhibits multiple 
enzymatic steps of adrenocortical steroid biosynthesis, potentially causing adrenal insufficiency. 
Recent studies in vitro have also documented a direct inhibitory effect of mitotane at the pituitary 
level. The present study was aimed to assess the hypothalamic pituitary adrenal axis in ACC 
patients receiving mitotane. 
DESIGN AND METHODS: We prospectively enrolled 16 patients on adjuvant treatment with 
mitotane after radical surgical resection of ACC, who underwent standard hormone evaluation and 
h-CRH stimulation. A group of 10 patients with primary adrenal insufficiency (PAI) served as 
controls for the CRH test. 
RESULTS: We demonstrated in ACC patients a close correlation between cortisol-binding 
globulin (CBG) and plasma mitotane levels, and a non-significant trend between mitotane dose and 
either serum or salivary cortisol. We did not find any correlation between the dose of cortisone 
acetate and either ACTH or cortisol levels. ACTH levels were significantly higher in the PAI than 
in ACC patients, both in baseline conditions [88.99 (11.04-275.00) vs 24.53 (6.16-121.88) pmol/L, 
p=0.031] and following CRH [158.40 (34.32-275.00) vs 67.43 (8.8-179.52) pmol/L p=0.016]. 
CONCLUSIONS: The observation of lower ACTH levels in patients with ACC than in patients 
with PAI, both in basal conditions and after CRH stimulation, suggests that mitotane may play an 
inhibitory effect on ACTH secretion at the pituitary levels. In conclusion, the present study shows 
that mitotane affects the HPA axis at multiple levels and no single biomarker may be used for the 
assessment of adrenal insufficiency. 
 
 
Abstract word count: 248 
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INTRODUCTION 
Mitotane has been employed in the treatment of adrenocortical cancer (ACC) over the last 50 
years and is generally regarded as a toxic drug with a narrow therapeutic index (1, 2, 3, 4, 5, 6). It is 
well known that mitotane is able to inhibit multiple enzymatic steps of adrenocortical steroid 
biosynthesis and for this reason mitotane has been used to treat Cushing’s syndrome of different 
etiologies (7). After the demonstration that adjunctive mitotane treatment following radical 
extirpation of ACC extends disease-free survival (8), mitotane has been increasingly used in an 
adjuvant post-operative setting (9, 10, 11,12).  
It is anticipated that patients adjuvantly treated with mitotane may develop adrenal insufficiency; 
thus, some clinicians prefer to initiate cortisol replacement concomitantly with mitotane (10,12). 
However, there is still limited knowledge on the impact of chronic mitotane treatment on the 
function of the hypothalamic pituitary adrenal (HPA) axis.  Since ACC is a very rare and aggressive 
tumor, the available studies did not focus on the consequences of chronic treatment with mitotane, 
but the issue of the mitotane-induced impairment of adrenal function is clinically relevant due to the 
improved prognosis of patients managed in referral centers following surgical removal of ACC (9, 
11,13). An obvious goal of steroid replacement is avoiding an adrenal crisis that may be difficult to 
recognize because symptoms of adrenal insufficiency mimic mitotane toxicity (e.g. asthenia, 
nausea) (14, 5). Although it is wise to err in favor of over-replacement, these patients should be 
spared from the complications of excessive steroid treatment; a challenging aim due to the usual 
practice of giving high doses of steroids in mitotane-treated patients. The rationale for this stands in 
the cytochrome P4503A4 induction by mitotane that results in rapid and massive inactivation of 
administered hydrocortisone (15).  
We have previously investigated the effects of mitotane on the endocrine system in patients 
treated adjunctively after complete ACC removal (16), showing that the drug was able to impair 
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adrenal hormone secretion and to increase cortisol-binding globulin (CBG). ACTH levels were 
found to be scattered with great individual variations. More recently, Gentilin and coworkers (17) 
showed that mitotane was able to affect corticotroph function and cell survival in the mouse 
pituitary cell line AtT20/D16v-F2 and in the primary cultures of human ACTH-secreting pituitary 
adenomas. Mitotane reduced cell viability and ACTH secretion by blocking the stimulatory effects 
of corticotropin releasing hormone (CRH) on cell viability, ACTH secretion, and POMC 
expression. These effects were apparent at mitotane doses greater than those usually necessary for 
reducing cortisol secretion in Cushing’s syndrome, but still in the therapeutic range for ACC 
treatment. This study coupled with previous evidence that mitotane was able to impair thyrotrope 
cell viability, TSH secretory activity, TSH expression, and TRH responsivity in T-T1 cells (18), 
supports the hypothesis that mitotane may have direct inhibitory effects at the pituitary level. 
Here we did a comprehensive assessment of the HPA axis in patients receiving mitotane as 
adjuvant treatment after radical resection of ACC to get insights on the pathophysiology of the HPA 
axis in this condition looking for markers of potential clinical interest.  
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SUBJECTS AND METHODS 
For the purpose of this study, we enrolled prospectively 16 consecutive patients who were managed 
at our center for adjuvant mitotane treatment between 2013 and 2015. Patients had radical (R0) 
resection of ACC, performed at least 1 year before (median 41 months) and followed by adjuvant 
mitotane treatment for at least 1 year (median 31 months). This series was homogeneous and 
representative of patients in mitotane adjuvant treatment. All patients were on a program of regular 
follow-up at our center.  
Patients were on stable mitotane dose and steroid supplementation since at least 6 months and were 
disease free at the time of evaluation. The institutional ethics committee of our hospital approved 
the study, and all patients provided written informed consent.  
Inclusion criteria for the study were: age ≥18, pathologically confirmed diagnosis of ACC 
(diagnoses were done or confirmed by the pathologists of San Luigi Hospital), availability of pre-
operative and post-operative computed tomography (CT) scans, ACC stage I-III at diagnosis, R0 
resection of primary tumor, complete follow-up information. Exclusion criteria were: incomplete 
tumor staging, ENSAT stage IV, history of other previous/concomitant malignancies, Rx or R1 
resection, follow-up of less than 12 months, or incomplete follow-up information. 
All patients received the same mitotane formulation (Lysodren, 500 mg tablets) orally at a starting 
dose of 1 g daily, with progressive weekly increments up to 4–6 g daily, or the highest tolerated 
dose, aiming to reach concentrations between 14–20 mg/L (19). When such or even higher 
concentrations were attained, doses were tapered with further individual dose adjustments guided 
by the results of mitotane measurement and toxicity assessment. Since the time when mitotane was 
commenced, all the patients received glucocorticoid replacement with a two-dose regimen of 
cortisone acetate (2/3 of dose in the morning at awakening, 1/3 of dose in the early afternoon). Due 
to the well-known enhanced metabolic clearance rate of glucocorticoids induced by mitotane (15) 
cortisone acetate was given at doses much higher than in Addison’s disease. The dose of cortisone 
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acetate was adjusted during mitotane treatment based on careful clinical assessment, according to 
our standard practice (14).  
A group of 10 patients with primary adrenal insufficiency served as controls for the CRH test. In 
five patients hypoadrenalism had an autoimmune origin (Addison’s disease), while in five patients 
it was due to bilateral adrenalectomy done in patients with previous Cushing's syndrome caused by 
ectopic ACTH secreting tumors, which were found and radically removed after adrenalectomy. 
 
Study protocol 
The study was done in an outpatient setting. A CRH test was performed between 0830 and 0900 h, 
after an overnight fast and omitting any hormone replacement in the morning. We deliberately set a 
minimum interval of 12 hours after the last dose of cortisone acetate. An antecubital vein was 
cannulated 30 min before the beginning of the test and blood samples were taken for measurement 
of plasma ACTH and serum cortisol at -15, 0, 15, 30, 45 and 60 after injection of human CRH 
(Ferring Arzneimittel GesmbH, Wien, Austria; 100 µg as an intravenous bolus). ACC patients also 
underwent routine laboratory evaluation, monitoring of mitotane concentrations and a hormonal 
work-up including determination of morning salivary cortisol, dehydroepiandrosterone sulfate 
(DHEAS), aldosterone, plasma renin activity (PRA), and cortisol binding globulin (CBG). In ACC 
patients, ACTH and cortisol levels were measured in the previous 12 months (a minimum of 6 
measurements) and their correlations with supplemental glucocorticoid dose were analyzed. PAI 
patients underwent only a CRH test. Blood samples for serum and plasma hormone analyzes 
were collected in tubes that did not contain any additives or contained K2-EDTA, 
respectively. The serum was obtained by centrifuging the tubes at 3000 rpm for 15 min at 
room temperature, while the plasma by centrifuging the tubes at 3000 rpm for 15 min at 4 °C. 
After separation from the red blood cells, serum and plasma were stored at 4-8°C if the assays were 
performed within 24 hours while, for longer storage periods, they were aliquoted and frozen at -
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20°C until assayed. Saliva was collected by chewing a cotton swab (Salivette, Sarstedt, Nümbrecht, 
Germany) over a 1-3 min period, centrifuged at 2000rpm for 10 min, aliquoted and frozen at -20°C.  
Hormones were measured in-house with commercially available reagents. Serum cortisol and serum 
DHEA-S were measured using competitive chemiluminescent enzyme immunoassay (Immulite 
2000, DPC, Los Angeles, CA). The following hormones were measured using radioimmunoassay 
(RIA): salivary cortisol (Radim, Pomezia, Rome, Italy), PRA (Sorin Biomedica, Saluggia, Italy), 
Aldosterone (Adaltis, Bologna, Italy), CBG (DIAsource, Ottignies Louvain la Neuve, Belgium). 
ACTH was measured with immunoradiometric assay (IRMA-Scantibodies Laboratory Inc., Santee, 
USA). The normal range and the detection limit of the different assays used in hormone monitoring 
were reported in Table 1. Intra- and inter-assay coefficients of variation for all hormone variables, 
performed in duplicate, were less than 5 and 9%, respectively. Plasma mitotane was measured in-
house by a HPLC assay, as described previously (20). Routine clinical chemistry variables were 
determined using standard enzymatic methods. 
 
Statistical analysis 
All statistical analyses were performed with Statistica (StatSoft) statistical software. For each 
patient, net and percentage ACTH and cortisol increments from baseline following CRH for both 
ACTH and cortisol were calculated. Rates and proportions were calculated for categorical data and 
medians and ranges for continuous data. Differences were analyzed by means of the chi-square test, 
Fisher’s exact test and Mann-Whitney U test. Correlation analyses were determined by calculating 
the Spearman’s R coefficient. P values of less than 0.05 were considered to indicate statistical 
significance.   
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
RESULTS 
The group of ACC patients included 10 men and 6 women, aged between 35 and 70 years 
(median 52 years). Their baseline characteristics are provided in Table 2. At the time of the study, 
6 patients had mitotane levels within the therapeutic range (14-20 mg/L) (19) and 1 had mitotane 
levels >20 mg/L, while 9 had mitotane levels <14 mg/L (<10 mg/L in 5 cases). The median dose of 
cortisone acetate was 62.5 mg daily (range 50-100 mg daily), corresponding to 33.1 mg/m2 of body 
surface (24.9 – 50.4 mg/m2) or 0.8 mg/kg (0.6 – 1.2 mg/kg). 
The group of PAI patients included 4 men and 6 women, aged between 32 and 63 years 
(median 54.5 years). In this group the median dose of cortisone acetate was 31.25 mg daily (range 
18.75 - 37.5 mg), corresponding to 15.9 mg/m2 of body surface (9.9 - 19.6 mg/m2) or 0.42 mg/kg 
(0.25 – 0.51 mg/kg).  
Hormonal data of the ACC patients are provided in Table 1. Basal serum cortisol was reduced in 14 
patients (87.5%), being undetectable in 7 of them (43.8%), and in the normal range in only 2 
patients (12.5%); one of them had low mitotane concentrations. Basal salivary cortisol was reduced 
in 14 patients (87.5%), being undetectable in 8 of them (50.0%), and in the normal range in only 2 
patients (the same cases as above). Only a non-significant trend between mitotane dose and either 
serum cortisol (Figure 1) or salivary cortisol was evident. However, 9 out of 11 patients with 
cortisol <100 nmol/L showed persistently elevated mitotane levels (in the target range) for at 
least 12 months preceding the study. Plasma ACTH levels were elevated in 11 patients (68.7%) 
and normal in 5 (31.3%). ACTH levels were not correlated with either plasma mitotane 
concentrations (Figure 2) or serum or salivary cortisol. Median CBG levels were of 2.92 µmol/L 
(0.94-3.90) being supranormal in 11 patients (68.7%), while DHEAS levels were undetectable 
(<0.4 µmol/L) in all patients. CBG levels were positively correlated with plasma mitotane 
concentrations (r=0.80, p=0.003). Only one patient was on mineralocorticoid replacement and the 
remainders had normal PRA (1.80, 0.60-5.10 µg/L/h) and aldosterone levels (0.33, 0.18-0.66 
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nmol/L). ACTH and cortisol levels measured in the previous 12 months did not show any 
correlation with glucocorticoid dose in use at the time of sampling. 
After CRH challenge, the median value of the net ACTH increment was 14.81 pmol/L (1.94 - 
39.49) and the median value of percent ACTH increment was 85% (-7 to 512); while the net 
cortisol increment was 41.38nmol/L (13.79 to 402.81), and the percent cortisol increment was 0% (-
35 to 246). The 2 patients with normal baseline cortisol levels showed no cortisol response to CRH 
while ACTH levels were elevated in one case and normal in the other and responding to CRH in 
both cases. An ACTH increment >35% was observed in 13 patients (81.2%) while only 3 patients 
(18.8%) had a cortisol increment >20%, however with negligible absolute values (<82.77 nmol/L). 
ACTH levels were significantly higher in PAI patients than in ACC patients, both in baseline 
conditions [88.99 (11.04-275.00) vs 24.53 (6.16-121.88) pmol/L, p=0.031] and following CRH 
[158.40 (34.32-275.00) vs 67.43 (8.8-179.52) pmol/L p=0.016]. 
The time dependent ACTH curves are showed in Figure 3.  
Baseline cortisol levels were superimposable between both groups. After CRH, percent cortisol 
increment was lower in ACC patients (p=0.041).  
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
DISCUSSION 
In the present study, we analyzed thoroughly the HPA axis in 16 consecutive patients treated 
adiuvantly with mitotane at a stable dose following radical resection of ACC. The patients were free 
of tumor at the time of evaluation and showed no obvious clinical or biochemical sign of under- or 
over-dosing of glucocorticoid replacement. Patients treated adjuvantly with mitotane represent the 
best model to assess the clinical and biochemical alterations associated with mitotane use without 
confounding due to the systemic and endocrine effects of the tumor (16). 
This study clearly shows that longstanding mitotane treatment almost invariably leads to adrenal 
insufficiency. Suppression of cortisol secretion was profound in most patients despite that a 
mitotane threshold >14 mg/L, that has been associated with the anti-neoplastic activity of the drug 
(19), was evident in only half of patients. However, 9 out of 11 patients with cortisol <100 
nmol/L had persistently elevated mitotane levels in the previous determinations, showing that 
adrenal suppression cannot be fully predicted by a single mitotane determination being more 
important the exposure to chronically elevated mitotane levels. The present study also 
underlines how challenging is maintaining mitotane concentrations in the therapeutic range (21).  
We reported that mitotane enhances serum CBG levels (16, 22) and we demonstrated a close 
correlation between CBG and mitotane levels. The mitotane-induced increase in CBG may partially 
mask the degree of cortisol suppression; thus, serum cortisol is generally regarded as an unreliable 
marker in mitotane-treated patients (22). Therefore, we have also assessed salivary cortisol in our 
patients, since cortisol levels in saliva reflect free cortisol (23) and may give a more accurate 
estimate of cortisol secretion independently from variation in CBG. Nevertheless, in our study the 
measurement of salivary cortisol did not add useful information for assessing adrenal insufficiency 
in mitotane-treated ACC patients. This is probably due to high levels of cortisone in salivary 
samples, because of the remarkable expression of 11β-hydroxysteroid dehydrogenase type 2 (11β-
HSD2) in salivary epithelium cell (24). It is known that in RIA-based cortisol assays specificity is 
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affected from cross-reactivity between cortisol and cortisone (25). We have deliberately excluded 
urinary free cortisol (UFC) from hormonal assessment, since in mitotane-treated patients UFC 
assessment is unreliable because of the possible cross-reactivity of immunoassays with different 
metabolites, such as 6β-hydroxycortisol, whose urinary excretion is largely increased as a result of 
increased metabolic clearance of exogenous steroids on mitotane treatment (15). Our patients took a 
median daily dose of cortisone acetate, corresponding to 33.1 mg/m2 or 0.8 mg/kg, which is higher 
than the median dose used in Addison’s disease (26). It is current practice to use much elevated 
cortisol doses to replace adrenal insufficiency in mitotane-treated patients because mitotane induces 
a strong induction of cytochrome P4503A4, leading to inactivation of exogenous steroids (15). We 
are aware that cortisone acetate is not the best drug for steroid replacement, but it was the most 
readily available exogenous steroid in Italy in the past years (27). 
Undetectable DHEAS levels in all patients may herald that 17α-hydroxylase is particularly 
sensitive to mitotane inhibition, as it was shown in vitro (28). Conversely, we confirm that the zona 
glomerulosa is relatively spared by the cytotoxic effect of mitotane (10, 12), since a single patient 
needed mineralocorticoid replacement. However, assessment of the renin-aldosterone axis may be 
confounded by the current high-dose cortisol replacement. 
ACTH levels were elevated in most but not all ACC patients. However, ACTH median values 
were less increased at baseline and were less responsive to CRH stimulation in ACC than in PAI 
patients. We consider unlikely that the reduced rise of ACTH may be fully explained by the high-
dose glucocorticoid replacement, since ACTH levels did not show any correlation with the dose of 
cortisone acetate over the previous 12 months. Therefore, the pattern of ACTH release following 
CRH stimulation may result from an inhibitory effect of mitotane on pituitary ACTH in agreement 
with previous in vitro data (17). 
In conclusion, our results show that mitotane affects the HPA axis at multiple levels and some of 
the induced alterations may confound interpretation of hormone tests. Therefore, it is impossible to 
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identify a single biomarker useful for the assessment of adrenal insufficiency and to guide hormone 
replacement in ACC patients treated with mitotane. The observation of lower ACTH levels in 
patients with ACC than in patients with PAI, both in basal conditions and after CRH stimulation, 
suggests that mitotane may play an inhibitory effect on ACTH secretion at the pituitary level. 
 
 
Declaration of interest: 
GR, SP, BZ, VB, LS, PP, SDF, MV, MCZ, SC have nothing to declare.  
MT, advisory board Millendo Therapeutics, advisory board HRA Pharma 
 
 
Funding: 
Grant IG 2015-17678 from AIRC to MT. 
 
 
  
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
References 
1. Pommier RF & Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 
1992 112 963-970; discussion 970-971. 
2. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, 
Alves VA, Zerbini MC, Liberman B, Carlos Gomes G & Kirschner MA. Adrenocortical carcinoma: 
clinical and laboratory observations. Cancer 2000 88 711-36. 
3. Dackiw AP, Lee JE, Gagel RF & Evans DB. Adrenal cortical carcinoma. World Journal of 
Surgery 2001 25 914-926. 
4. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M & Worden 
FP. Management of patients with adrenal cancer: recommendations of an international consensus 
conference. Endocrine-Related Cancer 2005 12 667-680. 
5. Allolio B & Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. Journal of 
Clinical Endocrinology and Metabolism 2006 91 2027-2037. 
6. Libè R, Fratticci A & Bertherat J. Adrenocortical cancer: pathophysiology and clinical 
management. Endocrine-Related Cancer 2007 14 13-28. 
7. Veytsman I, Nieman L & Fojo T. Management of endocrine manifestations and the use of 
mitotane as a chemotherapeutic agent for adrenocortical carcinoma. Journal of clinical oncology 
2009 27 4619-4629. 
8. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, 
Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker 
AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, 
Dogliotti L & Alfredo Berruti. Adjuvant mitotane treatment for adrenocortical carcinoma. The New 
England Journal of Medicine 2007 356 2372-2380. 
9. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich 
C, Quinkler M, Petersenn S, Spahn M, Hahner S & Allolio B, on behalf of the German ACC 
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
Registry Group. Improved survival in patients with stage II adrenocortical carcinoma followed up 
prospectively by specialized centers. Journal of Clinical Endocrinology and Metabolism 2010 95 
4925-4932. 
10. Fassnacht M, Kroiss M & Allolio B. Update in adrenocortical carcinoma. Journal of Clinical 
Endocrinology and Metabolism 2013 98 4551–4564. 
11. Else T, Williams AR, Sabolch A, Jolly S, Miller BS & Hammer GD. Adjuvant therapies and 
patient and tumor characteristics associated with survival of adult patients with adrenocortical 
carcinoma. Journal of Clinical Endocrinology and Metabolism 2014 99 455-461. 
12. Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L & Berruti A. Management of 
adrenal cancer: a 2013 update. Journal of Endocrinological Investigation 2014 37 207-217. 
13. Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, 
Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R & Habra MA. Adrenocortical 
carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. European 
Journal of Endocrinology 2013 169 891-899.  
14. Terzolo M & Berruti A. Adjunctive treatment of adrenocortical carcinoma. Current Opinion in 
Endocrinology, Diabetes & Obesity 2008 15 221-226. 
15. Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, Libé R, Allolio B, 
Bertagna X, Bertherat J, Beuschlein F, Fassnacht M, Karavitaki N, Mannelli M, Mantero F, 
Opocher G, Porfiri E, Quinkler M, Sherlock M, Terzolo M, Nightingale P, Shackleton CHL, 
Stewart PM, Hahner S & Arlt W. Mitotane therapy in adrenocortical cancer induces CYP3A4 and 
inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen 
replacement. European Journal of Endocrinology 98 2013161-171. 
16. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, Termine 
A, Di Carlo F, Dogliotti L, Angeli A, Berruti A & Terzolo M. Prospective evaluation of mitotane 
toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer 2008 15 
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
1043-1053. 
17. Gentilin E, Tagliati F, Terzolo M, Zoli M, Lapparelli M, Minoia M, Ambrosio MR, Degli 
Uberti EC, &Zatelli MC. Mitotane reduces human and mouse ACTH-secreting pituitary cell 
viability and function. Journal of Endocrinology 2013 218 275-285. 
18. Zatelli MC, Gentilin E, Daffara F, Tagliati F, Reimondo G, Carandina G, Ambrosio MR, 
Terzolo M & Degli Uberti EC. Therapeutic concentrations of mitotane (o,p'-DDD) inhibit 
thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. 
Endocrinology 2010 151 2453-2461. 
19. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, 
Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR & Baudin E. Plasma 
concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in 
adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. Journal of Clinical 
Endocrinology and Metabolism 2011 96 1844-1851. 
20. De Francia S, Pirro E, Zappia F, De Martino F, Sprio AE, Daffara F, Terzolo M, Berruti A, Di 
Carlo F  & Ghezzo F. A new simple HPLC method for measuring mitotane and its two principal 
metabolites Tests in animals and mitotane-treated patients. Journal of Chromatography B 2006 837 
69-75. 
21. Terzolo M, Zaggia B, Allasino B & De Francia S. Practical treatment using mitotane for 
adrenocortical carcinoma. Current Opinion in Endocrinology, Diabetes & Obesity 2014 21 159-
165. 
22. Alexandraki KI, Kaltsas GA, le Roux CW, Fassnacht M, Ajodha S, Christ-Crain M, Akker SA, 
Drake WM, Edwards R, Allolio B & Grossman AB. Assessment of serum-free cortisol levels in 
patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clinical Endocrinology 
2010 72 305-311. 
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
23. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM & Montori VM. 
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. Journal of 
Clinical Endocrinology and Metabolism 2008 93 1526-1540. 
24. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi KI, Fukushima K& Krozowski 
ZS. Localization of 11β-hydroxysteroid dehydrogenase type II in human epithelial tissues. Journal 
of Clinical Endocrinology and Metabolism 1996 81 3244-8. 
25. Vieira JG, Nakamura OH & Carvalho VM. Determination of cortisol and cortisone in human 
saliva by a liquid chromatography-tandem mass spectrometry method. Arq Bras Endocrinol 
Metabol 2014 58 844-50. 
26. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, 
Merke DP, Murad MH, Stratakis CA & Torpy DJ. Diagnosis and Treatment of Primary Adrenal 
Insufficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology 
and Metabolism 2016 101 364-89. 
27. Laureti S, Falorni A & Santeusanio F. Improvement of treatment of primary adrenal 
insufficiency by administration of cortisone acetate in three daily doses. J Endocrinol Invest 2003 
26 1071-5. 
28. Lehmann TP, Wrzesinski T & Jagodzinski PP. The effect of mitotane on viability, 
steroidogenesis and gene expression in NCI-H295R adrenocortical cells. Mol Med Rep 2013 7 893–
900. 
 
 
 
 
 
 
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
 
 
 
Figures Legends 
Figure 1: Correlation between morning serum cortisol levels and plasma mitotane levels in patients 
with ACC. r = correlation coefficient. 
 
Figure 2:  
Correlation between basal ACTH levels and plasma mitotane levels in patients with ACC. 
r = correlation coefficient.  
 
Figure 3:  
Comparison of time dependent ACTH curves during CRH test between patients with ACC and 
patients with Addison disease. Data are expressed as mean + SEM. 																		
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